Form 4: Halozyme Therapeutics SVP Awarded Restricted Stock Units for Patent Contribution

Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, was granted 20,137 restricted stock units (RSUs) in recognition of his contribution to a European patent issuance.

Summary

• Mark Howard Snyder, SVP and Chief Legal Officer at Halozyme Therapeutics, received 20,137 restricted stock units (RSUs) on June 12, 2024.
• The grant recognizes Snyder's contribution to the recent issuance of a European patent covering Halozyme's ENHANZE(R) rHuPH20 product.
• The RSUs vest one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

Sentiment

Score: 7

Explanation: The document reflects a positive event (granting of RSUs for patent contribution) and standard compensation practices. It suggests confidence in the executive's continued contributions.

Positives

• The grant of restricted stock units to Mr. Snyder recognizes his contribution to the company's intellectual property portfolio, specifically the European patent for ENHANZE(R) rHuPH20.
• The vesting schedule of the RSUs incentivizes continued contributions from Mr. Snyder over the next four years.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This announcement reflects a common practice in the biotechnology industry to incentivize and reward key personnel with equity-based compensation, aligning their interests with the company's long-term success. The European patent for ENHANZE(R) rHuPH20 is a valuable asset for Halozyme, and rewarding the individual responsible for securing it is a strategic move.

Comparison to Industry Standards

• Granting restricted stock units to key executives is a standard practice in the biotech industry to align their interests with shareholders.
• Companies like Amgen, Gilead, and Biogen also use RSUs as part of their compensation packages for senior management.
• The vesting schedule of one-fourth per year is also a common vesting schedule for RSUs in the industry.

Stakeholder Impact

• Shareholders may view this as a positive sign, as it incentivizes key personnel to continue contributing to the company's success.
• Employees may see this as a positive sign, as it demonstrates the company's commitment to rewarding its employees.

Key Dates